ARVINAS, INC. Deferred Revenue Recognized
ARVINAS, INC. (ARVN) reported Deferred Revenue Recognized of $152.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-04
- ARVINAS, INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $15.60M, a 91.74% decline year-over-year.
- ARVINAS, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $188.80M, a 646.25% increase year-over-year.
- ARVINAS, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $25.30M.
- ARVINAS, INC. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was -$31.40M.
- ARVINAS, INC. contract with customer, liability, revenue recognized for fiscal 2025 was $242.60M, a 140.20% increase from fiscal 2024.
- ARVINAS, INC. contract with customer, liability, revenue recognized for fiscal 2024 was $101.00M.
- ARVINAS, INC. contract with customer, liability, revenue recognized for fiscal 2023 was -$76.00M.
- ARVINAS, INC. contract with customer, liability, revenue recognized for fiscal 2022 was -$120.00M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 6 month as first filed | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 9 month as first filed | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $152.90M 10-Q · filed 2026-08-04 | |||||||
| 2026-03-31 | $15.60M 10-Q · filed 2026-05-11 | |||||||
| 2025-12-31 | $242.60M 10-K · filed 2026-02-24 | |||||||
| 2025-09-30 | $233.10M 10-Q · filed 2025-11-05 | |||||||
| 2025-06-30 | $211.20M 10-Q · filed 2026-08-04 | |||||||
| 2025-03-31 | $188.80M 10-Q · filed 2026-05-11 | |||||||
| 2024-12-31 | $101.00M 10-K · filed 2026-02-24 | -$101.00M 10-K · filed 2025-02-11 | ||||||
| 2024-09-30 | $82.00M 10-Q · filed 2025-11-05 | |||||||
| 2024-06-30 | $56.30M 10-Q · filed 2025-08-06 | |||||||
| 2024-03-31 | $25.30M 10-Q · filed 2025-05-01 | -$25.30M 10-Q · filed 2024-05-07 | ||||||
| 2023-12-31 | -$76.00M 10-K · filed 2025-02-11 | |||||||
| 2023-09-30 | $119.10M 10-Q · filed 2024-10-30 | -$119.10M 10-Q · filed 2023-11-07 | ||||||
| 2023-06-30 | $84.60M 10-Q · filed 2024-07-30 | -$84.60M 10-Q · filed 2023-08-08 | ||||||
| 2023-03-31 | -$31.40M 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | -$120.00M 10-K · filed 2024-02-27 | |||||||
| 2022-09-30 | -$85.80M 10-Q · filed 2023-11-07 | |||||||
| 2022-06-30 | -$55.50M 10-Q · filed 2023-08-08 | |||||||
| 2022-03-31 | -$24.20M 10-Q · filed 2023-05-05 | |||||||
| 2021-12-31 | -$18.60M 10-K · filed 2023-02-23 | $18.60M 10-K · filed 2022-02-28 | ||||||
| 2021-09-30 | -$20.30M 10-Q · filed 2022-11-09 | $16.61M 10-Q · filed 2021-11-03 | ||||||
| 2021-06-30 | -$11.10M 10-Q · filed 2022-08-04 | $11.08M 10-Q · filed 2021-08-05 | ||||||
| 2021-03-31 | -$5.50M 10-Q · filed 2022-05-05 | $5.54M 10-Q · filed 2021-05-04 | ||||||
| 2020-12-31 | $18.70M 10-K · filed 2022-02-28 | $18.65M 10-K · filed 2021-03-01 | ||||||
| 2020-09-30 | $17.32M 10-Q · filed 2020-11-05 | |||||||
| 2020-06-30 | $11.36M 10-Q · filed 2020-08-04 | |||||||
| 2020-03-31 | $5.18M 10-Q · filed 2020-04-28 | |||||||
| 2019-12-31 | $14.34M 10-K · filed 2021-03-01 | |||||||
| 2019-09-30 | $12.05M 10-Q · filed 2019-11-04 | |||||||
| 2019-06-30 | $8.03M 10-Q · filed 2019-08-05 | |||||||
| 2019-03-31 | $4.02M 10-Q · filed 2019-05-09 | |||||||
| 2018-12-31 | $13.55M 10-K · filed 2020-03-16 | |||||||
| 2018-09-30 | $10.35M 10-Q · filed 2018-11-14 | |||||||
| 2017-12-31 | $6.60M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |